» Articles » PMID: 36932387

Exosome-derived CircCCAR1 Promotes CD8 + T-cell Dysfunction and Anti-PD1 Resistance in Hepatocellular Carcinoma

Overview
Journal Mol Cancer
Publisher Biomed Central
Date 2023 Mar 18
PMID 36932387
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Circular RNAs (circRNAs) can be encapsulated into exosomes to participate in intercellular communication, affecting the malignant progression of a variety of tumors. Dysfunction of CD8 + T cells is the main factor in immune escape from hepatocellular carcinoma (HCC). Nevertheless, the effect of exosome-derived circRNAs on CD8 + T-cell dysfunction needs further exploration.

Methods: The effect of circCCAR1 on the tumorigenesis and metastasis of HCC was assessed by in vitro and in vivo functional experiments. The function of circCCAR1 in CD8 + T-cell dysfunction was measured by enzyme-linked immunosorbent assay (ELISA), western blotting and flow cytometry. Chromatin immunoprecipitation, biotinylated RNA pull-down, RNA immunoprecipitation, and MS2 pull-down assays were used to the exploration of mechanism. A mouse model with reconstituted human immune system components (huNSG mice) was constructed to explore the role of exosomal circCCAR1 in the resistance to anti-PD1 therapy in HCC.

Results: Increased circCCAR1 levels existed in tumor tissues and exosomes in the plasma of HCC patients, in the culture supernatant and HCC cells. CircCCAR1 accelerated the growth and metastasis of HCC in vitro and in vivo. E1A binding protein p300 (EP300) and eukaryotic translation initiation factor 4A3 (EIF4A3) promoted the biogenesis of circCCAR1, and Wilms tumor 1-associated protein (WTAP)-mediated m6A modification enhanced circCCAR1 stability by binding insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3). CircCCAR1 acted as a sponge for miR-127-5p to upregulate its target WTAP and a feedback loop comprising circCCAR1/miR-127-5p/WTAP axis was formed. CircCCAR1 is secreted by HCC cells in a heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1)-dependent manner. Exosomal circCCAR1 was taken in by CD8 + T cells and caused dysfunction of CD8 + T cells by stabilizing the PD-1 protein. CircCCAR1 promoted resistance to anti-PD1 immunotherapy. Furthermore, increased cell division cycle and apoptosis regulator 1 (CCAR1) induced by EP300 promoted the binding of CCAR1 and β-catenin protein, which further enhanced the transcription of PD-L1.

Conclusions: The circCCAR1/miR-127-5p/WTAP feedback loop enhances the growth and metastasis of HCC. Exosomal circCCAR1 released by HCC cells contributes to immunosuppression by facilitating CD8 + T-cell dysfunction in HCC. CircCCAR1 induces resistance to anti-PD1 immunotherapy, providing a potential therapeutic strategy for HCC patients.

Citing Articles

Sophisticated roles of tumor microenvironment in resistance to immune checkpoint blockade therapy in hepatocellular carcinoma.

Zhang Y, Ma Y, Ma E, Chen X, Zhang Y, Yin B Cancer Drug Resist. 2025; 8:10.

PMID: 40051497 PMC: 11883234. DOI: 10.20517/cdr.2024.165.


Plasma-Derived Neuronal Exosomal CircRNAs as Potential Biomarkers for Central Nervous System Infections.

Zhang R, Deng B, Shi S, Lu G, Xia J, Liang H J Immunol Res. 2025; 2025:9363390.

PMID: 40041405 PMC: 11879592. DOI: 10.1155/jimr/9363390.


The epigenetic hallmarks of immune cells in cancer.

Ji Y, Xiao C, Fan T, Deng Z, Wang D, Cai W Mol Cancer. 2025; 24(1):66.

PMID: 40038722 PMC: 11881328. DOI: 10.1186/s12943-025-02255-4.


m6A epitranscriptomic modification in hepatocellular carcinoma: implications for the tumor microenvironment and immunotherapy.

Liu F, Liu Q, Li X, Wang Y, Cao R, Zhang S Front Immunol. 2025; 16:1538658.

PMID: 40034695 PMC: 11873077. DOI: 10.3389/fimmu.2025.1538658.


Immunoregulatory role of exosomal circRNAs in the tumor microenvironment.

Lv C, Chen J, Wang Y, Lin Y Front Oncol. 2025; 15:1453786.

PMID: 40034598 PMC: 11872884. DOI: 10.3389/fonc.2025.1453786.


References
1.
Zhu A, Finn R, Edeline J, Cattan S, Ogasawara S, Palmer D . Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19(7):940-952. DOI: 10.1016/S1470-2045(18)30351-6. View

2.
Du L, Lee J, Jiang H, Wang C, Wang S, Zheng Z . β-Catenin induces transcriptional expression of PD-L1 to promote glioblastoma immune evasion. J Exp Med. 2020; 217(11). PMC: 7596815. DOI: 10.1084/jem.20191115. View

3.
Kim D, Kim H, Choi Y, Kim S, Lee J, Sung K . Exosomal PD-L1 promotes tumor growth through immune escape in non-small cell lung cancer. Exp Mol Med. 2019; 51(8):1-13. PMC: 6802663. DOI: 10.1038/s12276-019-0295-2. View

4.
Huang X, Zhang P, Wei C, Peng R, Lu J, Gao C . Circular RNA circMET drives immunosuppression and anti-PD1 therapy resistance in hepatocellular carcinoma via the miR-30-5p/snail/DPP4 axis. Mol Cancer. 2020; 19(1):92. PMC: 7236145. DOI: 10.1186/s12943-020-01213-6. View

5.
Zhou W, Cai Z, Liu J, Wang D, Ju H, Xu R . Circular RNA: metabolism, functions and interactions with proteins. Mol Cancer. 2020; 19(1):172. PMC: 7734744. DOI: 10.1186/s12943-020-01286-3. View